Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The calcium channel protein subunit alpha2delta (α2δ) is an auxiliary subunit of voltage-dependent calcium channels (VDCCs). It regulates the trafficking and surface expression of the pore-forming alpha1 subunit of high-voltage activated CaV channels (CaV1 and CaV2 families) and modulates channel biophysical properties. The α₂δ−1 subtype serves as the molecular target for gabapentinoid drugs used for treating neuropathic pain and epilepsy. Mutations or dysregulation in genes encoding certain isoforms have been linked to epilepsy, cerebellar ataxia, and neuropathic pain syndromes.
Gabapentinoids (e.g., gabapentin and pregabalin) bind to the α₂δ−1 and α₂δ−2 subunits of voltage-dependent calcium channels, reducing calcium influx and neurotransmitter release.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Calcium channel protein subunit alpha2delta (α2δ).